INVA | Innoviva, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	17.77 - 18.15
52 Week Range	14.33 - 21.28
Beta	0.53
Implied Volatility	66.12%
IV Rank	25.15%
Day's Volume	2,026,937
Average Volume	614,528
Shares Outstanding	62,601,100
Market Cap	1,116,803,624
Sector	Healthcare
Industry	Biotechnology
IPO Date	2004-10-05

Valuation
Profitability
Growth
Health
P/E Ratio	22.30
Forward P/E Ratio	N/A
EPS	0.80
1YR Price Target	17.75
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	112
Country	USA
Website	INVA

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

INVA's peers: GTX, EFTR, PLX, PDSB, LIFE, ELEV, DAWN, MRTX, AMLX, TERN, APLS, XFOR, INZY, HOOK, ABOS, FOLD, INCY, DNLI, ARGX, HRMY

*Chart delayed

Analyzing fundamentals for INVA we got that it has average fundamentals where Valuation is considered to be undervalued, Profitability is moderate, Growth is bad and Health is strong. For more detailed analysis please see INVA Fundamentals page.

Watching at INVA technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on INVA Technicals page.